Antithrombotic therapy in atrial fibrillation

Keyphrases

• Antithrombotic Therapy 100%
• Atrial Fibrillation 100%
• Anticoagulation 58%
• Cardioversion 50%
• Oral Vitamin K Antagonists 50%
• Risk Factors 33%
• Paroxysmal Atrial Fibrillation 33%
• Warfarin 33%
• Long-term Anticoagulation 33%
• Transesophageal Echocardiography 33%
• Ischemic Stroke 25%
• Heparin 16%
• Aspirin 16%
• Sinus Rhythm 16%
• Electrical Cardioversion 16%
• International Normalized Ratio 16%
• Thrombus 16%
• Low Molecular Weight Heparin 16%
• Risk of Ischemic Stroke 16%
• Vitamin K Antagonists 16%
• Pharmacological Cardioversion 16%
• Echocardiography Guided 16%
• Transient Ischemic Attack 8%
• Type 1 Diabetes Mellitus (T1DM) 8%
• High Risk 8%
• Clinical Practice Guidelines 8%
• Heart Failure 8%
• Intermediate Risk 8%
• Low Risk 8%
• History of Hypertension 8%
• Patient Values 8%
• Therapy Decision 8%
• Specific Types 8%
• Left Ventricular Systolic Function 8%
• Evidence-based Guidelines 8%
• Risky Driving 8%
• Elective Cardioversion 8%
• Systemic Embolism 8%
• Aspirin Therapy 8%
• Heart Valve Prosthesis 8%
• 8th Edition 8%
• American College of Chest Physicians 8%
• Prosthesis Type 8%
• Multiplane Transesophageal Echocardiography 8%
• Mitral Stenosis 8%
• Atrial Flutter 8%

Medicine and Dentistry

• Atrial Fibrillation 100%
• Antithrombotic Therapy 100%
• Anticoagulation 91%
• Cardioversion 75%
• Vitamin K Antagonist 66%
• Brain Ischemia 41%
• Transesophageal Echocardiography 41%
• Paroxysmal Atrial Fibrillation 33%
• Warfarin 33%
• Acetylsalicylic Acid 25%
• Sinus Rhythm 16%
• Heparin 16%
• Thrombus 16%
• Low Molecular Weight Heparin 16%
• Diabetes Mellitus 8%
• Retinol 8%
• Congestive Heart Failure 8%
• Contraindication 8%
• Systolic Function 8%
• Prosthesis 8%
• Transient Ischemic Attack 8%
• Clinical Guideline 8%
• Heart Valve Prosthesis 8%
• Mitral Valve Stenosis 8%
• Atrial Flutter 8%